UY38266A - Piridinil y pirazinil-(aza) indolsulfonamidas - Google Patents
Piridinil y pirazinil-(aza) indolsulfonamidasInfo
- Publication number
- UY38266A UY38266A UY0001038266A UY38266A UY38266A UY 38266 A UY38266 A UY 38266A UY 0001038266 A UY0001038266 A UY 0001038266A UY 38266 A UY38266 A UY 38266A UY 38266 A UY38266 A UY 38266A
- Authority
- UY
- Uruguay
- Prior art keywords
- aza
- pyrazinil
- indolsulfonamides
- pyridinil
- gpr17
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a piridinil y pirazinil-(aza) indolsulfonamidas que tienen actividad moduladora de GPR17. Los compuestos tienen utilidad en el tratamiento de una variedad de trastornos asociados con GPR17.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18178429 | 2018-06-19 | ||
| EP19157936 | 2019-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38266A true UY38266A (es) | 2020-01-31 |
Family
ID=67070797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038266A UY38266A (es) | 2018-06-19 | 2019-06-18 | Piridinil y pirazinil-(aza) indolsulfonamidas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11939319B2 (es) |
| EP (2) | EP4074703B1 (es) |
| JP (1) | JP7382973B2 (es) |
| KR (1) | KR20210022675A (es) |
| CN (1) | CN112469710B (es) |
| AU (1) | AU2019289788B2 (es) |
| BR (1) | BR112020025618A2 (es) |
| CA (1) | CA3100795A1 (es) |
| CL (1) | CL2020003202A1 (es) |
| DK (2) | DK3810591T3 (es) |
| ES (2) | ES2972491T3 (es) |
| FI (1) | FI4074703T3 (es) |
| HR (2) | HRP20221290T1 (es) |
| HU (2) | HUE060128T2 (es) |
| IL (1) | IL279428B2 (es) |
| LT (2) | LT4074703T (es) |
| MX (1) | MX2020012173A (es) |
| PL (2) | PL3810591T3 (es) |
| RS (2) | RS65272B1 (es) |
| SG (1) | SG11202012421TA (es) |
| SI (1) | SI4074703T1 (es) |
| UY (1) | UY38266A (es) |
| WO (1) | WO2019243303A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3137091A1 (en) * | 2019-06-17 | 2020-12-24 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis |
| CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
| TW202313569A (zh) * | 2021-06-04 | 2023-04-01 | 比利時商理溫醫療公司 | 吡咯基磺胺化合物 |
| WO2024017863A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel pyrimidinyl and triazinyl sulfonamide derivatives |
| WO2024017857A1 (en) * | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives |
| WO2024017856A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives |
| WO2024017855A1 (en) * | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds |
| WO2024017858A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel naphthyl and isoquinoline sulfonamide derivatives |
| WO2024042147A2 (en) * | 2022-08-26 | 2024-02-29 | F. Hoffmann-La Roche Ag | Novel deuterated pyrimidin-2-yl sulfonamide derivatives |
| WO2024104462A1 (en) * | 2022-11-20 | 2024-05-23 | Myrobalan Therapeutics Nanjing Co. Ltd | Gpr17 modulators and uses thereof |
| WO2024115733A1 (en) * | 2022-12-02 | 2024-06-06 | Rewind Therapeutics Nv | Fused pyrrolyl-sulfonamide compounds |
| WO2024153233A1 (en) * | 2023-01-19 | 2024-07-25 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as gpr17 antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| SE9904750D0 (sv) | 1999-12-23 | 1999-12-23 | Pharmacia & Upjohn Ab | New formulation, use and method |
| EP1741792B1 (en) | 2004-04-27 | 2010-11-03 | Takeda Pharmaceutical Company Limited | Novel ligand of g-protein-conjugated receptor protein and use thereof |
| ITMI20042007A1 (it) | 2004-10-21 | 2005-01-21 | Consiglio Nazionale Ricerche | "modulatori del ricettore gpr17 e loro impieghi terapeutici" |
| AU2006338165B2 (en) | 2005-12-20 | 2010-10-28 | Teikoku Pharma Usa, Inc. | Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same |
| DE112008002309A5 (de) | 2007-06-25 | 2010-05-27 | Acino Ag | Elektrophoretisches transdermales Applikationssystem |
| GB2491520A (en) | 2010-03-11 | 2012-12-05 | Jerry Swinford | Method and apparatus for washing downhole tubulars and equipment |
| IT1402549B1 (it) | 2010-11-03 | 2013-09-13 | Univ Pisa | Composti e composizioni che modulano gpr17 e loro usi terapeutici e diagnostici |
| EP2567698B1 (en) | 2011-09-07 | 2014-02-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | GPR 17 agonists and screening assay |
| JP6082457B2 (ja) | 2012-05-09 | 2017-02-15 | ウニヴェルスィタ デッリ ストゥディ ディ ミラノ | Ｇｐｒ１７受容体調節因子 |
| TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
-
2019
- 2019-06-18 CN CN201980040596.9A patent/CN112469710B/zh active Active
- 2019-06-18 ES ES22171413T patent/ES2972491T3/es active Active
- 2019-06-18 IL IL279428A patent/IL279428B2/en unknown
- 2019-06-18 PL PL19733686.0T patent/PL3810591T3/pl unknown
- 2019-06-18 DK DK19733686.0T patent/DK3810591T3/da active
- 2019-06-18 HU HUE19733686A patent/HUE060128T2/hu unknown
- 2019-06-18 RS RS20240230A patent/RS65272B1/sr unknown
- 2019-06-18 EP EP22171413.2A patent/EP4074703B1/en active Active
- 2019-06-18 WO PCT/EP2019/065967 patent/WO2019243303A1/en unknown
- 2019-06-18 KR KR1020217001631A patent/KR20210022675A/ko not_active Application Discontinuation
- 2019-06-18 US US17/058,845 patent/US11939319B2/en active Active
- 2019-06-18 LT LTEP22171413.2T patent/LT4074703T/lt unknown
- 2019-06-18 MX MX2020012173A patent/MX2020012173A/es unknown
- 2019-06-18 CA CA3100795A patent/CA3100795A1/en active Pending
- 2019-06-18 PL PL22171413.2T patent/PL4074703T3/pl unknown
- 2019-06-18 FI FIEP22171413.2T patent/FI4074703T3/fi active
- 2019-06-18 EP EP19733686.0A patent/EP3810591B1/en active Active
- 2019-06-18 SG SG11202012421TA patent/SG11202012421TA/en unknown
- 2019-06-18 LT LTEPPCT/EP2019/065967T patent/LT3810591T/lt unknown
- 2019-06-18 HR HRP20221290TT patent/HRP20221290T1/hr unknown
- 2019-06-18 SI SI201930697T patent/SI4074703T1/sl unknown
- 2019-06-18 ES ES19733686T patent/ES2929992T3/es active Active
- 2019-06-18 JP JP2020570915A patent/JP7382973B2/ja active Active
- 2019-06-18 HR HRP20240071TT patent/HRP20240071T1/hr unknown
- 2019-06-18 RS RS20221001A patent/RS63760B1/sr unknown
- 2019-06-18 AU AU2019289788A patent/AU2019289788B2/en active Active
- 2019-06-18 DK DK22171413.2T patent/DK4074703T3/da active
- 2019-06-18 UY UY0001038266A patent/UY38266A/es not_active Application Discontinuation
- 2019-06-18 BR BR112020025618-8A patent/BR112020025618A2/pt unknown
- 2019-06-18 HU HUE22171413A patent/HUE065411T2/hu unknown
-
2020
- 2020-12-10 CL CL2020003202A patent/CL2020003202A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003202A1 (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| CL2019001660A1 (es) | (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas. | |
| PH12020551397A1 (en) | Cot modulators and methods of use thereof | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| CL2017001464A1 (es) | Modulación inmunológica | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CR20160425A (es) | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas | |
| CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
| MX2020012823A (es) | Alcoxipiridinil indolsulfonamidas sustituidas. | |
| EA201891607A1 (ru) | Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| TR201903840T4 (tr) | İnsan tamamlayıcı C5'e bağlanan polipeptitler. | |
| EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b | |
| EA201792157A1 (ru) | Имидазопиразиноны в качестве ингибиторов pde1 | |
| TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
| CL2020000056A1 (es) | Nuevos derivados de xantina sustituidos. | |
| BR112017008481A2 (pt) | composto antimicótico | |
| EA201691108A1 (ru) | Хиназолин-thf-амины в качестве ингибиторов pde1 | |
| EA202191342A1 (ru) | Модуляторы экспрессии irf5 | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201203 |